Idiopathic Pulmonary Fibrosis

Respiratory·MeSH: Idiopathic Pulmonary Fibrosis

Prevalence

18.0 / 100K

Incidence

6.8 / 100K/yr

37 drugs in development·28 companies·22 clinical trials

Drug Pipeline by Phase

Approved(7)

Drug	Company
etorel	GYRE THERAPEUTICS, INC. (GYRE)
nintedanib	Aptinyx Inc. (APTX)
nintedanib	NYMOX PHARMACEUTICAL CORP (NYMXF)
nintedanib	EXELIXIS, INC. (EXEL)
nintedanib	DR REDDYS LABORATORIES LTD (RDY)
nintedanib	X4 Pharmaceuticals, Inc (XFOR)
pirfenidone	Amneal Pharmaceuticals, Inc. (AMRX)

Phase 3(5)

Drug	Company
deupirfenidone	PureTech Health plc (PRTC)
hec585	SUNSHINE BIOPHARMA INC. (SBFM)
Inhaled treprostinil	UNITED THERAPEUTICS Corp (UTHR)
mnkd-101	MANNKIND CORP (MNKD)
pirfenidone	PureTech Health plc (PRTC)

Phase 2(12)

Drug	Company
Bexotegrast (PLN-74809)	PLIANT THERAPEUTICS, INC. (PLRX)
env-101	Generate Biomedicines Inc. (GENB)
gri-0621	GRI Bio, Inc. (GRI)
ifetroban	CUMBERLAND PHARMACEUTICALS INC (CPIX)
lti-03	Rein Therapeutics, Inc. (RNTX)
mn-001	MEDICINOVA INC (MNOV)
nal er	Trevi Therapeutics, Inc. (TRVI)
pipe-791 dose a	Contineum Therapeutics, Inc. (CTNM)
pipe-791 dose b	Contineum Therapeutics, Inc. (CTNM)
PLN-74809	PLIANT THERAPEUTICS, INC. (PLRX)
tti-101	Tvardi Therapeutics, Inc. (TVRD)
Vasculan	CUMBERLAND PHARMACEUTICALS INC (CPIX)

Phase 1(7)

Drug	Company
ABBV-142	AbbVie Inc. (ABBV)
ANPA-0073	Structure Therapeutics Inc. (GPCR)
ARO-MMP7	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ARO-MMP7 Inhalation Solution	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Axatilimab	Syndax Pharmaceuticals Inc (SNDX)
mnkd-201	MANNKIND CORP (MNKD)
nintedanib	SUNSHINE BIOPHARMA INC. (SBFM)

Preclinical(4)

Drug	Company
cb5138-3	COHBAR, INC. (COBU)
chit1 small molecule	Ocean Biomedical, Inc. (OCEA)
LTSE-2578	Structure Therapeutics Inc. (GPCR)
REC-4209	RECURSION PHARMACEUTICALS, INC. (RXRX)

Phase 4(2)

Drug	Company
BMS-986278	BRISTOL MYERS SQUIBB CO (BMY)
inhaled treprostinil	UNITED THERAPEUTICS Corp (UTHR)

BioSniper tracks 37 drugs in development for Idiopathic Pulmonary Fibrosis across 28 companies.

There are 22 clinical trials targeting Idiopathic Pulmonary Fibrosis tracked by BioSniper.

The estimated prevalence of Idiopathic Pulmonary Fibrosis is approximately 18.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.